Ladenburg Thalmann Downgrades Eyenovia(EYEN.US) to Hold Rating
Eyenovia Price Target Cut to $2.00/Share From $12.00 by HC Wainwright & Co.
William Blair Downgrades Eyenovia(EYEN.US) to Hold Rating
Eyenovia Analyst Ratings
Brookline Capital Downgrades Eyenovia(EYEN.US) to Hold Rating
Ladenburg Thalmann Maintains Eyenovia(EYEN.US) With Buy Rating, Cuts Target Price to $4.5
Eyenovia Analyst Ratings
HC Wainwright & Co. Reiterates Buy on Eyenovia, Maintains $12 Price Target
Eyenovia's Promising Growth Prospects: Buy Rating Affirmed by Analyst
Eyenovia Analyst Ratings
HC Wainwright & Co. Reiterates Buy on Eyenovia, Maintains $12 Price Target
Eyenovia's Strategic Collaborations and Innovative Optejet System Underpin Buy Rating
H.C. Wainwright Maintains Eyenovia(EYEN.US) With Buy Rating, Maintains Target Price $12
HC Wainwright & Co. Reiterates Buy on Eyenovia, Maintains $12 Price Target
Eyenovia Analyst Ratings
Analysts Offer Insights on Healthcare Companies: Eyenovia (EYEN), Alpine Immune Sciences (ALPN) and GoodRx Holdings (GDRX)
HC Wainwright & Co. : The Eynovia (EYEN.US) rating was reaffirmed and adjusted from buy to buy, with a target price of $12.00.
Eyenovia Analyst Ratings
HC Wainwright & Co. Reiterates Buy on Eyenovia, Maintains $12 Price Target
Eyenovia Analyst Ratings